Common back claims do not always explain your soreness

A scan finding may not be the sore spot

Disc wear and small bulges become common as people grow older. Many people have those changes without a sore back. A useful scan must fit the place, timing, and type of your symptoms.

Does the report settle the matter? Not by itself; your doctor compares it with your strength, feeling, reflexes, and daily limits. A scan is most helpful when the result could change your care.

Don’t let one phrase frighten you.

A disc can also look different later, while soreness may ease before any picture changes. This is shown: scan findings and symptoms don’t always match. A single cause may be suggested, but it can remain unknown.

A treatment name does not promise a result

Words such as regenerative or advanced can sound final. Those words don’t prove a disc will rebuild or that soreness will stop. PRP uses a prepared part of your own blood, yet results for the spine remain mixed.

Ask what the treatment is meant to improve. The honest aim may be easier movement or less soreness, not a new-looking scan. Also ask about cost, recovery time, and what comes next if it doesn’t help.

At home, note how sitting time, walking, and sleep change the ache. Keep activity within a range you can manage again tomorrow. QC Kinetix provides consultations and biologic therapies for back soreness when non-surgical choices are being considered.

Sources

1. A systematic review of 33 studies imaging 3,110 people WITHOUT back pain found disc degeneration in 37% of 20-year-olds rising to 96% of 80-year-olds, disc bulges in 30% rising to 84%, disc protrusions in 29% rising to 43%, and annular fissures in 19% rising to 29%. The authors conclude that many degenerative imaging features are part of normal ageing and unassociated with pain.

   Brinjikji W, Luetmer PH, Comstock B, et al. — Systematic literature review of imaging features of spinal degeneration in asymptomatic populations.. American Journal of Neuroradiology, 2015. DOI: 10.3174/ajnr.A4173.

2. A meta-analysis of six randomised trials and 1,804 patients found that immediate lumbar imaging - x-ray, CT or MRI - produced no significant difference in pain, function, quality of life, mental health, global improvement or satisfaction versus usual care WITHOUT immediate imaging, at either short-term or 6-12 month follow-up. Clinicians are advised to refrain from routine imaging in the absence of features suggesting serious pathology.

   Chou R, Fu R, Carrino JA, Deyo RA — Imaging strategies for low-back pain: systematic review and meta-analysis.. The Lancet, 2009. DOI: 10.1016/S0140-6736(09)60172-0.

3. A meta-analysis of 11 cohort studies found that lumbar disc herniations spontaneously RESORB in about two thirds of conservatively treated cases (pooled incidence 66.66%), documented on repeat CT or MRI. A herniated disc on a scan is not a permanent structural verdict, and the natural course is a confounder in every uncontrolled report of a disc procedure.

   Zhong M, Liu JT, Jiang H, et al. — Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis.. Pain Physician, 2017.

4. The FDA states verbatim that stem cell products, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been 'approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' No stem cell product is approved in the United States for any orthopedic use: the only ones with FDA approval at all are blood-forming cells derived from umbilical cord blood, approved solely for disorders of blood production, and there are currently no FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA.gov, 2025.

5. In January 2025 federal district court orders permanently banned the co-founders of the Stem Cell Institute of America and several related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. On summary judgment the court found the defendants had published false and misleading advertisements about the efficacy and approval of stem cell injections for a range of conditions. Their clinic charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties.. FTC.gov, 2025.

6. A survey of internet-based marketing claims documented that direct-to-consumer promotion of unapproved stem cell interventions - long assumed to be a feature of countries with lax regulation - is widespread among businesses based in the United States, and concluded that regulatory agencies must better oversee this marketplace.

   Turner L, Knoepfler P — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

7. A double-blind trial randomised 78 people with painful, MRI-confirmed, unhealed osteoporotic vertebral fractures to vertebroplasty or a SHAM procedure. Vertebroplasty produced no significant advantage on any measured outcome at any time point, while both groups improved substantially. The lesson generalises well beyond vertebroplasty: a procedure that reliably makes patients feel better in an open trial can be indistinguishable from a convincing fake once the comparison is blinded.

   Buchbinder R, Osborne RH, Ebeling PR, et al. — A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures.. New England Journal of Medicine, 2009. DOI: 10.1056/NEJMoa0900429.

8. In a randomised trial of 97 adults with chronic low back pain, three weeks of OPENLY LABELLED placebo pills - patients were told outright they were placebos - added to usual care produced a 1.5-point pain reduction and a 2.9-point disability improvement versus 0.2 and 0.0 for usual care alone, with moderate to large effect sizes. Any uncontrolled 'our patients improved' claim about a back procedure has to clear this bar first.

   Carvalho C, Caetano JM, Cunha L, et al. — Open-label placebo treatment in chronic low back pain: a randomized controlled trial.. Pain, 2016. DOI: 10.1097/j.pain.0000000000000700.